首页 | 本学科首页   官方微博 | 高级检索  
     

喹硫平联合碳酸锂或丙戊酸钠治疗双相躁狂的多中心随机对照研究
引用本文:金卫东,陈炯,王鹤秋,邱德胜,徐乐平,范学胜,陈群,罗小年,李植荣. 喹硫平联合碳酸锂或丙戊酸钠治疗双相躁狂的多中心随机对照研究[J]. 中国新药与临床杂志, 2006, 25(12): 893-897
作者姓名:金卫东  陈炯  王鹤秋  邱德胜  徐乐平  范学胜  陈群  罗小年  李植荣
作者单位:1. 浙江省立同德医院、浙江省精神卫生研究院,浙江,杭州,310012
2. 武汉大学人民医院精神科,湖北,武汉,430060
3. 全军精神卫生中心,江苏,常州,213003
4. 中国医科大学附属第一医院精神科,辽宁,沈阳,110012
5. 首都医科大学附属安定医院,北京,100088
6. 汕头市精神病医院,广东,汕头,515000
摘    要:目的:探讨喹硫平合并碳酸锂或丙戊酸钠治疗双相躁狂的疗效和安全性。方法:将符合CCMD-3和DSM-IV的双相障碍诊断标准的100例研究对象随机分成2组,53例喹硫平组应用喹硫平合并碳酸锂或丙戊酸钠,47例对照组单一使用碳酸锂或丙戊酸钠,治疗观察6 wk。采用Beck-Rafaelsen躁狂量表(BRMS)评定疗效,以副反应量表(TESS)及实验室有关辅助检查评价安全性。结果:喹硫平组的45例(85%)和对照组的40例(85%)完成了6 wk的治疗观察,喹硫平组在治疗wk 1末的减分率比对照组显著,这种差异在1~6 wk一直存在,而且wk 6结束后的临床有效率(BRMS减分率≥50%)、痊愈率(BRMS<11)也显著高于对照组。喹硫平合并碳酸锂或丙戊酸钠常见的不良反应有头晕、头痛、嗜睡、心悸、口干、直立性低血压、便秘。结论:喹硫平合并碳酸锂或丙戊酸钠治疗双相躁狂的疗效比单一使用心境稳定剂好。

关 键 词:喹硫平  双相情感障碍  随机对照试验  多中心研究  心境稳定剂
文章编号:1007-7669(2006)12-0893-05
收稿时间:2006-03-06
修稿时间:2006-03-062006-08-28

Quetiapine combined with lithium carbonate or sodium valproate for treatment of bipolar mania: a randomized, multicenter, and controlled study
JIN Wei-dong,CHEN Jiong,WANG He-qiu,QIU De-sheng,XU Le-ping,FAN Xue-sheng,CHEN Qun,LUO Xiao-nian,LI Zhi-rong. Quetiapine combined with lithium carbonate or sodium valproate for treatment of bipolar mania: a randomized, multicenter, and controlled study[J]. Chinese Journal of New Drugs and Clinical Remedies, 2006, 25(12): 893-897
Authors:JIN Wei-dong  CHEN Jiong  WANG He-qiu  QIU De-sheng  XU Le-ping  FAN Xue-sheng  CHEN Qun  LUO Xiao-nian  LI Zhi-rong
Abstract:AIM: To study the efficacy and safety of quetiapine combined with lithium carbonate or sodium valproate in the treatment of patients with bipolar mania. METHODS: One hundred patients met with the diagnositic criteria of bipolar mania in CCMD-3 and DSM-IV were randomly divided into study group (quetiapine combined with lithium carbonate or sodium valproate) 53 patients, and control group (lithium carbonate or sodium valproate alone) 47 patients, and observed the outcomes for 6 wk of each. The Beck-Rafaelsen Manic Scale (BRMS) and TESS were separately used for the assessments of efficacy and safety. RESULTS: Forty-five patients (85 %) of 53 in the study group and the 40 patients (85 %) of 47 in the control group completed the study. A significantly greater mean reduction with it's rate in total BRMS score was observed at different periods time in study group comparing with those in the control group. The response rate (≥50 % BRMS improvement) was significantly higher in the study group than in control group (79.2 % vs 46.8 %, P < 0.01) , as well as the proportion of patients achieving clinical remission (BRMS < 11) (58.4 % vs 29.8 %, P < 0.01). The mean therapeutic dose of quetiapine was (655±s 151) mg·d-1 in patients met with the response criteria. Common adverse reactions in the study group included dizziness, headache, somnolence, palpitation, dry mouth, postural hypotension, constipation. CONCLUSION: The effects of quetiapine combined with lithium carbonate or sodium valproate in the treatment of bipolar manic episode are better than those of lithium carbonate or sodium valproate used alone.
Keywords:quetiapine   bipolar mood disorder   randomized controlled trial   multicenter study   mood stabilizers
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号